Fourth, although hematocrit increases with SGLT2 inhibitors might have favorable effects in patients with coronary artery disease, in DAPA-HF, there was no difference in the magnitude of benefit of dapagliflozin in patients with or without an ischemic cardiomyopathy. This evidence concerns the gene SLC5A2 and hydrops fetalis.